Fenna de Vries Adrianus A J Smit Gertjan Wolbink Annick de Vries Floris C Loeff Eric J F Franssen
10.3389/fonc.2022.960116
Front Oncol
2023 Jan 11;12:960116.
immune-related adverse events immunotherapy pembrolizumab pharmacodynamic (pd) pharmacokinetic (pk) programmed cell death protein 1 (pd-1)
CC BY
https://pubmed.ncbi.nlm.nih.gov/36713570/
Case Reports
PMC9875126
36713570
Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non-small cell lung cancer after a single 200 mg administration
2023